Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-28. Numbers and descriptions here follow the published literature rather than marketing material.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
== Discovery == NAPE-PLD is an enzyme activity - a phospholipase, acting on phospholipids found in the cell membrane. It is not homology but the chemical outcome of its activity that classes it as phospholipase D. The enzymatic activity was discovered and characterized in a series of experiments culminating in the 2004 publication of a biochemical purification scheme from which peptide sequencing could be accomplished. Researchers homogenized (finely ground) hearts from 150 rats and subjected the resulting crude lysate to sucrose sedimentation at 105,000 x g to separate the cell membranes from the remainder of the cell. The integral membrane proteins were then solubilized using octyl glucoside and subjected to four column chromatography steps (HiTrap SP HP cation-exchange column, HiTrap Q anion-exchange column, HiTrap Blue affinity column, Bio-Gel HTP hydroxyapatite column). Each of these separates the different types of membrane proteins into different sample containers when the proteins are eluted from the column over time, and by measuring the activity of samples in each container it was possible to track which ones received the active enzyme. Measurement of the enzyme activity was done by thin layer chromatography of a radioactive substrate sensitive to the NAPE-PLD enzymatic activity: Cleavage of the substrate affected where it appeared on the plate when the radiation was detected on a bioimaging analyzer.
For example, a butterfly may produce offspring with new mutations. The majority of these mutations will have no effect; but one might change the colour of one of the butterfly's offspring, making it harder (or easier) for predators to see. If this color change is advantageous, the chances of this butterfly's surviving and producing its own offspring are a little better, and over time the number of butterflies with this mutation may form a larger percentage of the population. Neutral mutations are defined as mutations whose effects do not influence the fitness of an individual. These can increase in frequency over time due to genetic drift. It is believed that the overwhelming majority of mutations have no significant effect on an organism's fitness. Also, DNA repair mechanisms are able to mend most changes before they become permanent mutations, and many organisms have mechanisms, such as apoptotic pathways, for eliminating otherwise-permanently mutated somatic cells. Beneficial mutations can improve reproductive success.
Bryant Park is a 9.6-acre (3.9 ha), privately managed public park in the New York City borough of Manhattan. It is located between Fifth Avenue and Avenue of the Americas (Sixth Avenue) and between 40th and 42nd Streets in Midtown Manhattan. The eastern half of Bryant Park is occupied by the Main Branch of the New York Public Library. The western half contains a lawn, shaded walkways, and amenities such as a carousel, and is located entirely over an underground structure that houses the library's stacks. The park hosts several events, including a seasonal "Winter Village" with an ice rink and shops during the winter. The first park at the site was opened in 1847 and was called Reservoir Square due to its proximity to the Croton Distributing Reservoir. Reservoir Square contained the New York Crystal Palace, which hosted the Exhibition of the Industry of All Nations in 1853 and burned down in 1858. The square was renamed in 1884 for abolitionist and journalist William Cullen Bryant. The reservoir was demolished in 1900 and the New York Public Library's main branch was built on the site, opening in 1911. Bryant Park was rebuilt in 1933–1934 to a plan by Lusby Simpson. After a period of decline, it was restored in 1988–1992 by landscape architects Hanna/Olin Ltd. and architects Hardy Holzman Pfeiffer Associates, during which the park was rebuilt and the library's stacks were built underneath. Further improvements were made in the late 20th and early 21st centuries.
=== Ba–Bee === David Baker (b. 1962). American biochemist and computational biologist at the University of Washington, who studies methods to predict and design the three-dimensional structures of proteins. Nobel Prize in chemistry, 2024. Tania A. Baker (PhD 1988). American biochemist at MIT, who has studied transposons and enzymes that catalyse protein unfolding. Member Natl. Acad. Sci. USA. Clinton Ballou (1923–2021). American biochemist at UC Berkeley, whose research focused on the metabolism of carbohydrates and the structures of microbial cell walls. Member Natl. Acad. Sci. USA. Horace Barker (1907–2000). American biochemist and microbiologist at UC Berkeley. Member Natl. Acad. Sci. USA. David Bartel (PhD 1993). American biochemist at MIT, known for work on microRNA biology. Member Natl. Acad. Sci. USA. Bonnie Bassler (b. 1962). American molecular biologist at Princeton, known for studies of quorum sensing, and the idea that disruption of chemical signalling can be used as an antimicrobial therapy. Member Natl. Acad. Sci. USA. Philip A. Beachy (b. 1958). American biochemist at Stanford, known for studies to understand the molecular mechanisms behind the growth of multicellular embryos, especially the role of the Hedgehog signalling pathway. Member Natl. Acad. Sci. USA. Jon Beckwith (b. 1935). American microbiologist and geneticist at Harvard who made important contributions to the study of bacterial genetics. Member Natl. Acad. Sci. USA.
Sources: en.wikipedia.org
== Synthesis == PFOA has two main synthesis routes, electrochemical fluorination (ECF) and telomerization. The ECF route sees octanoyl chloride (the acid chloride of octanoic acid) reacted with hydrofluoric acid. Multiple products are formed by ECF with the target acid fluoride F(CF2)7COF being produced as only 10–15% of the yield, while the main products are perfluorinated cyclic ether isomers, including FC-75. This acid fluoride is hydrolyzed to yield PFOA as a mixture of straight-chain (78%), terminally branched (13%), and internally branched (9%) molecules, because ECF induces rearrangements in the carbon tail of the acid chloride. ECF also results in production wastes. 3M synthesized ECF PFOA at their Cottage Grove, Minnesota facility from 1947 to 2002 and was the world's largest producer. ECF production continues on a smaller scale in Europe and Asia. PFOA is also synthesized by the telomerization represented below, where the telogen is the organoiodine compound and the taxogen is the tetrafluoroethylene. Each step is an addition reaction where the carbon-iodine bond of the telogen is added across the carbon-carbon double bond of the unsaturated taxogen, resulting in the formation of a new telogen.
In October 2024, the Maryland Department of Transportation's evaluation committee awarded a 20-year contract to run concessions operations at BWI to URW/Harbor Bankshare, a partnership between Unibail-Rodamco-Westfield and The Harbor Bank of Maryland, which was approved by the Board of Public Works in February 2025. During the 2024 legislative session, Moore introduced the Families Serve Act, which would allow employers to give preference to military dependents in hiring; and the Time to Serve Act, which doubles the amount of days of leave state employees can take to fulfill duties in military reserves. He also supported bills to ban discrimination toward military members in hiring. Both bills passed and were signed into law. In February 2025, Moore announced several state government initiatives to hire federal workers and contractors displaced by the Trump administration's mass layoffs, and called on private sector and nonprofit entities in the state to do the same. In June 2025, he announced to state employees that the state would seek to cut about $121 million from the state's personnel budget through a combination of employee buy-out offers, a hiring freeze, and the elimination of at least 150 vacant positions. The state also put on hold its expedited hiring program for federal workers affected by mass layoffs. 502 state government positions were eliminated as a result of the Moore administration's workforce reduction efforts, including 332 positions that were eliminated after workers agreed to buyouts.
The UPMC Rooney Sports Complex is a multipurpose, multisport training, sports science, and sports medical complex located along the shore of the Monongahela River in Pittsburgh and is unique in that it combines training facilities for the University of Pittsburgh football team and the Pittsburgh Steelers NFL team in one location with an academically based sports science and medicine program. The complex consists of four centers which include the Center for Sports Medicine, Sports Training Center, Indoor Training Center, and the Fitness and Conditioning Center.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.